Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial
Elisabeth Bahlmann-Kroll, Sebastian Häckl, Stefanie Kramer, Vera Christine Wulfmeyer, Julian Glandorf, Jessica Kaufeld, Armin Koch, Dagmar Hartung, Bernhard M W Schmidt, Kai Schmidt-Ott, Roland Schmitt · 2024
Read Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial by Elisabeth Bahlmann-Kroll, Sebastian Häckl, Stefanie Kramer, Vera Christine Wulfmeyer, Julian Glandorf, Jessica Kaufeld, Armin Koch, Dagmar Hartung, Bernhard M W Schmidt, Kai Schmidt-Ott, Roland Schmitt (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11647394.txt.
Description
Polycystic kidney disease slowly replaces working kidney tissue with cysts, and only one drug is approved to slow it. Elisabeth Bahlmann-Kroll and ten co-authors publish the protocol for EMPA-PKD, a trial testing whether empagliflozin, a diabetes drug from a class never trialed in this disease, is safe for these patients. Some fear the drug class could even speed cyst growth, which the trial is built to detect.
Forty-four patients with fast-progressing disease will take the drug or a placebo for eighteen months, split by whether they already use the approved therapy. Kidney volume growth on MRI is the main readout, with filtration rate, hormones, and blood pressure also tracked. The protocol, approved by German regulators, appears in 2024.
Catalog record
| CREATOR | Elisabeth Bahlmann-Kroll, Sebastian Häckl, Stefanie Kramer, Vera Christine Wulfmeyer, Julian Glandorf, Jessica Kaufeld, Armin Koch, Dagmar Hartung, Bernhard M W Schmidt, Kai Schmidt-Ott, Roland Schmitt |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |